Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
33
ELAN Quote, Financials, Valuation and Earnings
Last price:
$9.45
Seasonality move
:
3.58%
Day range:
$9.26 - $9.48
52-week range:
$8.02 - $18.80
Dividend yield:
0%
P/E ratio:
14.12x
P/S ratio:
1.06x
P/B ratio:
0.77x
Volume:
4.4M
Avg. volume:
5.3M
1-year change:
-27.45%
Market cap:
$4.7B
Revenue:
$4.4B
EPS (TTM):
$0.67
Analysts' Opinion
-
Consensus RatingElanco Animal Health has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.86, Elanco Animal Health has an estimated upside of 46.55% from its current price of $9.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.50 representing 100% downside risk from its current price of $9.46.
Fair Value
-
According to the consensus of 12 analysts, Elanco Animal Health has 46.55% upside to fair value with a price target of $13.86 per share.
ELAN vs. S&P 500
-
Over the past 5 trading days, Elanco Animal Health has overperformed the S&P 500 by 7.17% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Elanco Animal Health does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Elanco Animal Health revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Elanco Animal Health reported revenues of $1B.
Earnings Growth
-
Elanco Animal Health earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Elanco Animal Health reported earnings per share of -$0.02.
Enterprise value:
8.5B
EV / Invested capital:
--
Price / LTM sales:
1.06x
EV / EBIT:
11.83x
EV / Revenue:
1.93x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
22.50x
Price / Operating cash flow:
12.36x
Enterprise value / EBITDA:
6.17x
Gross Profit (TTM):
$2.4B
Return On Assets:
2.48%
Net Income Margin (TTM):
7.61%
Return On Equity:
5.48%
Return On Invested Capital:
2.98%
Operating Margin:
0.78%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4.4B | $4.4B | $4.4B | $1B | $1B | |
| Gross Profit | $2.5B | $2.5B | $2.4B | $519M | $519M | |
| Operating Income | $384M | $326M | $251M | $10M | $8M | |
| EBITDA | $851M | -$224M | $1.4B | $111M | $159M | |
| Diluted EPS | -$0.16 | -$2.50 | $0.67 | -$0.29 | -$0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.4B | $3.3B | $3.3B | $3.4B | $3.2B | |
| Total Assets | $17.7B | $16.5B | $15.5B | $14.4B | $12.6B | |
| Current Liabilities | $2.1B | $1.6B | $1.7B | $1.2B | $1.3B | |
| Total Liabilities | $9.2B | $9B | $8.2B | $8.1B | $6.5B | |
| Total Equity | $8.5B | $7.5B | $7.3B | $6.2B | $6.1B | |
| Total Debt | $6.1B | $6.3B | $5.8B | $5.8B | $4.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $452M | $271M | $541M | $157M | $177M | |
| Cash From Investing | -$179M | -$169M | $1.2B | -$35M | -$90M | |
| Cash From Financing | -$549M | -$83M | -$1.5B | -$139M | -$32M | |
| Free Cash Flow | $268M | $117M | $380M | $116M | $124M | |
ELAN
Sector
Market Cap
$4.7B
$35M
Price % of 52-Week High
50.32%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-27.45%
-38.53%
Beta (5-Year)
1.436
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.78
200-day SMA
Sell
Level
$12.47
Bollinger Bands (100)
Sell
Level
9.93 - 12.39
Chaikin Money Flow
Buy
Level
5.8M
20-day SMA
Buy
Level
$9.19
Relative Strength Index (RSI14)
Buy
Level
50.09
ADX Line
Buy
Level
33.76
Williams %R
Sell
Level
-12.462
50-day SMA
Sell
Level
$10.20
MACD (12, 26)
Buy
Level
0.97
25-day Aroon Oscillator
Sell
Level
-60
On Balance Volume
Sell
Level
-15.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.0566)
Buy
CA Score
(Annual)
Level (-0.2937)
Buy
Beneish M-Score
(Annual)
Level (-2.5701)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-3.2527)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Stock Forecast FAQ
In the current month, ELAN has received 5 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ELAN average analyst price target in the past 3 months is $13.86.
-
Where Will Elanco Animal Health Stock Be In 1 Year?
According to analysts, the consensus estimate is that Elanco Animal Health share price will rise to $13.86 per share over the next 12 months.
-
What Do Analysts Say About Elanco Animal Health?
Analysts are divided on their view about Elanco Animal Health share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Elanco Animal Health is a Sell and believe this share price will drop from its current level to $9.50.
-
What Is Elanco Animal Health's Price Target?
The price target for Elanco Animal Health over the next 1-year time period is forecast to be $13.86 according to 12 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ELAN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Elanco Animal Health is a Hold. 7 of 12 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ELAN?
You can purchase shares of Elanco Animal Health via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Elanco Animal Health shares.
-
What Is The Elanco Animal Health Share Price Today?
Elanco Animal Health was last trading at $9.45 per share. This represents the most recent stock quote for Elanco Animal Health. Yesterday, Elanco Animal Health closed at $9.46 per share.
-
How To Buy Elanco Animal Health Stock Online?
In order to purchase Elanco Animal Health stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 28
Saia [SAIA] is down 2.29% over the past day.
Sell
48
APPF alert for Apr 28
AppFolio [APPF] is up 4.33% over the past day.
Sell
15
KNSL alert for Apr 28
Kinsale Capital Group [KNSL] is up 1.37% over the past day.
